CRISPR Therapeutics AG
CRSP
$43.34
-$2.19-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M |
| Total Depreciation and Amortization | 4.84M | 4.74M | 4.85M | 4.83M | 4.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.79M | 14.65M | 15.49M | 11.02M | 13.65M |
| Change in Net Operating Assets | -24.35M | -40.36M | 10.49M | 210.49M | -203.97M |
| Cash from Operations | -50.03M | -106.91M | -95.58M | 109.75M | -96.07M |
| Capital Expenditure | -254.00K | -219.00K | -707.00K | -721.00K | -738.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 106.08M | -161.39M | -126.20M | -97.08M | -80.72M |
| Cash from Investing | 105.83M | -161.60M | -126.91M | -97.80M | -81.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.88M | 9.64M | -- | 305.93M | 38.94M |
| Repurchase of Common Stock | -- | -- | -466.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16.88M | 9.64M | -466.00K | 305.93M | 38.94M |
| Foreign Exchange rate Adjustments | -87.00K | 75.00K | 2.00K | -11.00K | 61.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -1.00K |
| Net Change in Cash | 72.59M | -258.80M | -222.95M | 317.88M | -138.53M |
